Key result
Tc-99m sestamibi uptake improves substantially from acute to chronic phases in both takotsubo cardiomyopathy phenotypes.
Why the study?
The precise pathophysiological mechanism of takotsubo cardiomyopathy is unclear, prompting this study to clarify the nuclear characteristics, degree of myocardial damage, and serial changes in TTC and rTTC using myocardial perfusion imaging.
Does myocardial perfusion imaging using Tc-99m sestamibi show serial changes from acute to chronic phases in patients with takotsubo and reverse takotsubo cardiomyopathy?
Observational (n=28)
Does myocardial perfusion imaging using Tc-99m sestamibi show serial changes from acute to chronic phases in patients with takotsubo and reverse takotsubo cardiomyopathy?
Myocardial perfusion imaging with Tc-99m sestamibi demonstrates reversible reduction in uptake during the acute phase of takotsubo and reverse takotsubo cardiomyopathy, suggesting transient microcirculatory or cellular dysfunction.
May support serial MPI for monitoring takotsubo recovery; leaves open impact on management or prognosis.
BACKGROUND: Takotsubo cardiomyopathy (TTC) shows reversible hypokinesis in the left ventricular (LV) apical-half segment and hyperkinesis in the LV basal-half segment. However, the precise pathophysiological mechanism of TTC is unclear. Therefore, this study sought to clarify the nuclear characteristics, degree of myocardial damage, and serial change of TTC and rTTC using myocardial perfusion imaging. METHODS: We performed myocardial perfusion scintigraphy in 28 patients (TTC: 20, rTTC: 8) using Tc-99m sestamibi and assessed minimum percentage uptake (min-%-uptake), extent score (ES) and summed rest score (SRS) at acute and chronic phases. RESULTS: Min-%-uptake improved from the acute to the chronic phase (TTC: 54 [48-59]% vs 87 [81-90]%, P < 0.01; rTTC: 60 [55-64]% vs 77 [71-79]%, P < 0.01), as did the ES (TTC: 32 [26-41]% vs 0.0 [0.0-6.0]%, P < 0.01; rTTC: 16 [12-34]% vs 0.0 [0.0-0.0]%, P = 0.02) and SRS (TTC: 4.5 [3.9-5.3] vs 0.0 [0.0-0.2], P < 0.01; rTTC: 3.6 [3.3-3.8] vs 0.0 [0.0-0.0], P = 0.01). CONCLUSION: Tc-99m sestamibi uptake was reduced in hypokinetic regions in the acute phase and improved in the chronic phase. TTC and rTTC may involve a reversible disorder of the myocardial cell membrane, mitochondria, and microcirculation.
No takes yet. Share an insight, caveat, or question.
Miyajima et al. (2021) conducted an observational in Takotsubo and reverse takotsubo cardiomyopathy (n=28). Myocardial perfusion scintigraphy using Tc-99m sestamibi vs. Chronic phase (vs acute phase) was evaluated on Minimum percentage uptake (min-%-uptake) in takotsubo cardiomyopathy (p=<0.01). Tc-99m sestamibi minimum percentage uptake improved significantly from the acute to chronic phase in both takotsubo (54% vs 87%, P<0.01) and reverse takotsubo cardiomyopathy (60% vs 77%, P<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: